A Descriptive Study of the Efficacy and Safety of ONGLYZA (Saxagliptin) Under Conditions of Actual Use in the Philippines.
Phase of Trial: Phase IV
Latest Information Update: 07 Oct 2013
At a glance
- Drugs Saxagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Acronyms ONGLYZA-PMS
- Sponsors AstraZeneca
- 01 Dec 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 12 Jul 2012 Additional lead trial investigators identified as reported by ClinicalTrials.gov.
- 25 Oct 2010 New trial record